Prudential Financial Inc. Lowers Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Prudential Financial Inc. trimmed its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 61.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,364 shares of the biotechnology company’s stock after selling 96,700 shares during the period. Prudential Financial Inc. owned about 0.28% of Enanta Pharmaceuticals worth $347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in ENTA. JPMorgan Chase & Co. raised its stake in shares of Enanta Pharmaceuticals by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after acquiring an additional 85,082 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Enanta Pharmaceuticals by 34.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock worth $1,109,000 after buying an additional 49,050 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $254,000. Wellington Management Group LLP bought a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at about $360,000. Finally, State Street Corp lifted its stake in Enanta Pharmaceuticals by 6.4% in the third quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after acquiring an additional 27,147 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ENTA has been the topic of a number of research reports. JMP Securities reissued a “market outperform” rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $4.26 on Friday. Enanta Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $17.24. The firm has a 50-day simple moving average of $6.31 and a two-hundred day simple moving average of $7.72. The firm has a market cap of $90.88 million, a price-to-earnings ratio of -0.86 and a beta of 0.69.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly purchased 45,000 shares of the stock in a transaction on Wednesday, February 12th. The stock was acquired at an average price of $5.69 per share, with a total value of $256,050.00. Following the completion of the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 13.89% of the stock is currently owned by corporate insiders.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.